Bellio H, Roussot N, Bertaut A, Hervieu A, Zanetta S, Tharin Z, Vincent J, Bengrine L, Hennequin A, Guion JF, Boudrant A, Collot T, Ghiringhelli F, Fumet JD

Future Oncol. 2025 02 6;:1-8

Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial.

Thibaudin M, Roussot N, Burlot C, Schmitt A, Vincent J, Tharin Z, Bengrine L, Bellio H, Bertaut A, Hampe L, Daumoine S, Rederstorff E, Peroz M, Huppe T, Derangère V, Rageot D, Simard J, Truntzer C, Fumet JD, Ghiringhelli F

Signal Transduct Target Ther. 2025 01 17;10(1):22

Intracranial response of brain metastases in patients with HER2-amplified breast cancer treated with trastuzumab-deruxtecan after failure of tucatinib-based therapy.

Desmoulins I, Bellio H, Méjean N, Truntzer C, Ladoire S

Eur J Cancer. 2023 05 9;187:161-163

[New drug approval: Nivolumab for adjuvant treatment of patients with PD-L1-positive (≥1%), muscle invasive urothelial carcinoma who are at high risk of recurrence after radical resection].

Bellio H, Benderra MA

Bull Cancer. 2022 08 19;:

Small Cell Neuroendocrine Carcinoma of the Paranasal Sinuses with Unexpected Location and Clinical Presentation and Occupational Exposure: A Case Report.

Tankere P, Zanetta S, Kaderbhai CG, Bellio H, Lagrange A, Garcier M, Ghiringhelli F

Am J Case Rep. 2022 Mar 2;23:e934980

Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.

Reda M, Macaire P, Bellio H, Uwer L, Ilie S, Lorgis V, Hennequin A, Ladoire S, Rederstorff E, Fumoleau P, Isambert N, Bonnin N, You B, Freyer G, Desmoulins I, Schmitt A

Cancer Chemother Pharmacol. 2022 Jan 8;: